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Abstract: Organometallic Ir(III) cyclopentadienyl complexes [(η5-Cpx)Ir(C^N)Cl], 
Cp
x
 = Cp*, C
^
N = 2-(p-tolyl)pyridine (1), 2-phenylquinoline (2), 
2-(2,4-difluorophenyl)pyridine (3), Cp
x
 = tetramethyl(phenyl)cyclopentadienyl 
(Cp
xph
), C
^
N = 2-phenylpyridine (4), and Cp
x
 = 
tetramethyl(biphenyl)cyclopentadienyl (Cp
xbiph
), C
^
N = 2-phenylpyridine (5), have 
been synthesized and characterized. The X-ray crystal structures of 2 and 5 have been 
determined and show typical “piano-stool” geometry. All the complexes hydrolyzed 
rapidly in aqueous solution (<5 min) even at 278 K. The pKa values of the aqua 
adducts 1A−5A are in the range of 8.31−8.87, and follow the order 1A > 2A > 4A > 
5A ≈ 3A. Hydroxo-bridged dimers {[(η5-Cpx)Ir]2(μ-OD)3}
+
 (Cp
x
 = Cp*, 6; Cp
xph
, 7; 
Cp
xbiph
, 8) are readily formed during pH titrations at ca. pH 8.7. Complexes 1 and 3−5 
bind strongly to 9-ethylguanine (9-EtG), moderately strongly to 9-methyladenine 
(9-MeA), and hence preferentially to 9-EtG when in competition with 9-MeA. The 
extent of guanine and adenine binding to complex 2 was significantly lower for both 
purines due to steric hindrance from the chelating ligand. All complexes showed 
potent cytotoxicity, with IC50 values ranging from 6.5 μM to 0.7 μM towards A2780 
human ovarian cancer cells. Potency toward these cancer cells increased with 
additional phenyl substitution on Cp*: Cp
xbiph
 > Cp
xph
 > Cp*. Cp
xbiph
, with complex 5 
exhibiting sub-micromolar activity (2× as active as cisplatin). These data demonstrate 
how the aqueous chemistry, nucleobase binding and anticancer activity of C,N-bound 
Ir
III
 cyclopentadienyl complexes can be controlled and fine-tuned by the modification 
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of the chelating and cyclopentadienyl ligands. 
 
 
*To whom correspondence should be addressed. E-mail: P.J.Sadler@warwick.ac.uk. 
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Introduction 
Organometallic complexes offer enormous scope for the design of anticancer 
candidates due to their versatile structures, potential redox features and wide range of 
ligand substitution rates.
1
 For examples, titanocenyl, ferrocenyl and Ru
II
 arene 
anticancer complexes are attracting current attention.
2
 However, there are only a 
limited number of reported studies on the anticancer activity of organometallic 
iridium complexes.
3
 In general iridium(III) complexes are usually thought to be 
relatively inert.
4
 
The negatively-charged pentamethylcyclopentadienyl ligand (Cp*) is often an 
excellent stabilizing ligand for organometallic iridium(III) complexes. However, a 
number of Cp* Ir
III
 complexes of the type [(η5-C5Me5)Ir(XY)Cl]
0/+
, where XY = 
N,N-bound 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane),
3i
 ethylenediamine (en), 
2,2′-bipyridine (bpy), 1,10-phenanthroline (phen), or N,O-bound picolinate (pico),3a 
have been reported to be inactive towards A2780 human ovarian cancer cells. 
However, the electronic and steric properties of the ligands can have a major effect on 
the chemical and biological activities of transition metal complexes.
5
 Recently we 
have demonstrated that introduction of phenyl or biphenyl substituents on Cp* can 
improve cancer cell cytotoxicity of N,N-chelated Ir
III
 complexes significantly.
3a
 In 
addition, we have found that replacement of the neutral N,N-bound chelating ligand 
(bpy) by the negatively-charged C,N-bound 2-phenylpyridine (phpy) ligand in a Cp* 
Ir
III
 chlorido complex can switch on biological activity.
3b
 This finding has led us to 
make detailed investigations of Cp* Ir
III
 complexes with C,N-bound ligands and to 
study the influence of phenyl- or biphenyl-substituted Cp* on their chemical and 
biological properties.  
We report studies of the aqueous chemistry (hydrolysis, acidity of the resultant aqua 
adducts), nucleobase binding and cancer cell toxicity of Ir
III
 complexes containing 
C,N-chelating ligands based on 2-phenylpyridine with electron-donating or 
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electron-withdrawing substituents, and with Cp* and substituted Cp* ligands, Chart 1. 
The results suggest that this new class of organometalic Ir(III) complexes is well 
suited for development as anticancer agents. 
 
Chart 1. Iridium Cyclopentadienyl Complexes Studied in This Work 
N
N
N N
FF
phpy tpy phq dfphpy
CpxbiphCp* Cpxph
Ir
Cpx
Z
C
N
0/+
Cpx
C^N
 
Z=Cl Z=D2O Z=9-EtG Z=9-MeA Cp
x
 C^N 
1 1A 1G 1Ad Cp* tpy 
2 2A 2G 2Ad Cp* phq 
3 3A 3G 3Ad Cp* dfphpy 
4 4A 4G 4Ad Cp
xph
 phpy 
5 5A 5G 5Ad Cp
xbiph
 phpy 
 
 
 
Experimental Section 
Materials. 2-Phenylpyridine, 2-(2,4-difluorophenyl)pyridine, 2-(p-tolyl)pyridine, 
2-phenylquinoline, 9-ethylguanine, and 9-methyladenine were purchased from 
Sigma-Aldrich. Methanol was distilled over magnesium/iodine prior to use. Dimers 
CpxIr
D
O
D
O
O
D
IrCpx
dimer Cpx
Cpxph
Cpxbiph
7
8
Cp*6
+
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[(η5-C5Me5)IrCl2]2,
6
 [(η5-C5Me4C6H5)IrCl2]2,
3a
 and [(η5-C5Me4C6H4C6H5)IrCl2]2,
3a
 
were prepared according to reported methods.  
Syntheses.  
[(η5-C5Me5)Ir(tpy)Cl] (1). A solution of [(η
5
-C5Me5)IrCl2]2 (48 mg, 0.06 mmol), 
2-(p-tolyl)pyridine (20 mg, 0.12 mmol) and sodium acetate (20 mg, 0.24 mmol) in 
CH2Cl2 (15 mL) was stirred for 2 h at ambient temperature. The solution was filtered 
through celite. The filtrate was evaporated to dryness on a rotary evaporator, and 
washed with diethyl ether. The product was recrystallized from CHCl3/hexane. Yield: 
45 mg (70%). 
1
H NMR (CDCl3): δ = 8.65 (d, 1H, J = 5.7 Hz), 7.75 (d, 1H, J = 8.3 
Hz), 7.62 (m, 2H), 7.57 (d, 1H, J = 8.0 Hz), 7.03 (t, 1H, J = 6.3 Hz), 6.86 (d, 1H, J = 
7.8 Hz), 1.68 (s, 15H). 
13
C NMR (CDCl3): δ = 151.29, 140.79, 136.74, 128.35, 
123.27, 121.65, 118.43, 88.41, 77.36, 8.83. Anal. Calcd. for C22H25ClNIr (531.14): C, 
49.75; H, 4.74; N, 2.64. Found: C, 49.66; H, 4.65; N, 2.68. MS: m/z 496 [M − Cl]+. 
[(η5-C5Me5)Ir(phq)Cl] (2). The synthesis was performed as for 1 using 
[(η5-C5Me5)IrCl2]2 (48 mg, 0.06 mmol), 2-phenylquinoline (25 mg, 0.12 mmol), and 
sodium acetate (20 mg, 0.24 mmol). Yield: 43 mg (75%). 
1
H NMR (CDCl3): δ = 8.71 
(d, 1H, J = 8.8 Hz), 8.02 (d, 1H, J = 8.7 Hz), 7.93 (d, 2H, J = 8.8 Hz), 7.77 (m, 2H), 
7.69 (t, 1H, J = 8.1 Hz), 7.53 (t, 1H, J = 6.7 Hz), 7.24 (t, 1H, J = 7.8 Hz), 7.07 (t, 1H, 
J = 7.7 Hz), 1.57 (s, 15H). 
13
C NMR (CDCl3): δ = 156.22, 137.76, 136.49, 131.36, 
130.87, 130.33, 127.97, 126.34, 125.30, 122.11, 116.56, 89.11, 77.35, 76.71, 9.26. 
Anal. Calcd. for C25H25ClNIr (567.13): C, 52.94; H, 4.44; N, 2.47. Found: C, 53.06; 
H, 4.41; N, 2.42. MS: m/z 531 [M − Cl]+. Crystals suitable for X-ray diffraction were 
obtained by slow evaporation of a methanol/diethyl ether solution at ambient 
temperature. 
[(η5-C5Me5)Ir(dfphpy)Cl] (3). The synthesis was performed as for 1 using 
[(η5-C5Me5)IrCl2]2 (48 mg, 0.06 mmol), 2-(2,4-difluorophenyl)pyridine (23 mg, 0.12 
mmol), and sodium acetate (20 mg, 0.24 mmol). Yield: 46 mg (70%). 
1
H NMR 
(CDCl3): δ = 8.71 (d, 1H, J = 6.0 Hz), 8.19 (d, 1H, J = 8.8 Hz), 7.69 (t, 1H, J = 8.0 
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Hz), 7.31 (d, 1H, J = 8.8 Hz), 7.10 (t, 1H, J = 6.3 Hz), 6.49 (t, 1H, J = 9.5 Hz), 1.67 (s, 
15H). 
13
C NMR (CDCl3): δ = 151.54, 143.53, 137.52, 122.7, 117.28, 98.20. 89.02, 
77.35, 8.78. Anal. Calcd. for C21H21ClF2NIr (553.10): C, 45.60; H, 3.83; N, 2.53. 
Found: C, 45.76; H, 3.71; N, 2.46. MS: m/z 517 [M − Cl]+. 
[(η5-C5Me4C6H5)Ir(phpy)Cl] (4). A solution of [(η
5
-C5Me4C6H5)IrCl2]2 (46 mg, 
0.05 mmol), 2-phenylpyridine (15 mg, 0.10 mmol) and sodium acetate (16 mg, 0.20 
mmol) in CH2Cl2 (15 mL) was heated under reflux in an N2 atmosphere for 24 h. The 
solution was filtered through celite. The filtrate was evaporated to dryness on a rotary 
evaporator and washed with diethyl ether. The product was recrystallized from 
CHCl3/hexane. Yield: 37 mg (57%). 
1
H NMR (MeOD-d4): δ = 8.60 (d, 1H, J = 5.3 
Hz), 8.04 (d, 1H, J = 8.3 Hz), 7.84 (m, 2H), 7.65 (d, 1H, J = 7.8 Hz), 7.38 (m, 3H), 
7.33 (m, 2H), 7.16 (t, 1H, J = 6.1 Hz), 7.13 (t, 1H, J = 7.2 Hz), 7.09 (t, 1H, J = 7.3 
Hz), 1.85 (s, 3H), 1.74 (s, 3H),1.72 (s, 3H), 1.56 (s, 3H). 
13
C NMR (CDCl3): δ = 
151.53, 137.13, 135.65, 131.14, 128.77, 127.33, 123.90, 122.20, 118.96, 77.35, 9.66. 
Anal. Calcd. for C26H25ClNIr (579.16): C, 53.92; H, 4.35; N, 2.42. Found: C, 53.77; 
H, 4.31; N, 2.41. MS: m/z 543 [M − Cl]+. 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (5). The synthesis was performed as for 4 using 
[(η5-C5Me4C6H4C6H5)IrCl2]2 (53 mg, 0.05 mmol), 2-phenylpyridine (15 mg, 0.10 
mmol) and sodium acetate (16 mg, 0.20 mmol). Yield: 37 mg (57%). 
1
H NMR 
(CDCl3): δ = 8.51 (d, 1H, J = 5.3 Hz), 7.81 (d, 1H, J = 7.3 Hz), 7.72 (m, 2H), 7.64 (m, 
5H), 7.51 (m, 4H), 7.37 (d, 1H, J = 7.6 Hz), 7.16 (t, 1H, J = 7.3 Hz), 7.05 (t, 1H, J = 
6.0 Hz), 6.94 (t, 1H, J = 7.3 Hz), 1.92 (s, 3H), 1.82 (s, 3H),1.79 (s, 3H), 1.67 (s, 3H). 
13
C NMR (CDCl3): δ = 151.45, 139.90, 136.98, 135.57, 131.05, 129.01, 127.22, 
123.93, 122.51, 118.94, 77.34, 9.88. Anal. Calcd. for C32H29ClNIr (655.25): C, 58.66; 
H, 4.46; N, 2.14. Found: C, 58.46; H, 4.35; N, 2.18. MS: m/z 619 [M − Cl]+.Crystals 
suitable for X-ray diffraction were obtained by slow evaporation of a 
methanol/diethyl ether solution at ambient temperature. 
Methods and Instrumentation.  
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X-ray crystallography. All diffraction data were obtained on an Oxford 
Diffraction Gemini four-circle system with a Ruby CCD area detector using Mo Kα 
radiation. Absorption corrections were applied using ABSPACK.
7
 The crystals were 
mounted in oil and held at 100(2) K with the Oxford Cryosystem Cobra. The 
structures were solved by direct methods using SHELXS (TREF)
8
 with additional 
light atoms found by Fourier methods. Complexes 2 and 5 were refined against F
2
 
using SHELXL
9
, and hydrogen atoms were added at calculated positions and refined 
riding on their parent atoms.  
X-ray crystallographic data for complexes 2 and 5 have been deposited in the 
Cambridge Crystallographic Data Centre under the accession numbers CCDC 829525 
and 829524, respectively. 
NMR Spectroscopy. 
1
H NMR spectra were acquired in 5 mm NMR tubes at 298 K 
(unless stated otherwise) on either Bruker DPX 400 (
1
H = 400.03 MHz) or AVA 600 
(
1
H = 600.13 MHz) spectrometers. 
1
H NMR chemical shifts were internally 
referenced to CHCl3 (7.26 ppm) for chloroform-d1, CHD2OD (3.33 ppm) for 
methanol-d4 or to 1,4-dioxane (3.75 ppm) for aqueous solutions. All data processing 
was carried out using XWIN-NMR version 3.6 (Bruker UK Ltd.). 
Mass Spectrometry. Electrospray ionization mass spectra (ESI-MS) were obtained 
on a Bruker Esquire 2000 Ion Trap Spectrometer. Samples were prepared in 50% 
CH3CN and 50% H2O (v/v). The mass spectra were recorded with a scan range of m/z 
50–1000 for positive ions.  
Elemental Analysis. CHN elemental analyses were carried out on a CE-440 
elemental analyzer by Exeter Analytical (UK) Ltd. 
pH Measurement. pH* values (pH meter reading without correction for the effect 
of deuterium on the glass electrode) of NMR samples in D2O were measured at ca. 
298 K directly in the NMR tube, before and after recording the NMR spectra, using a 
Corning 240 pH meter equipped with a micro combination electrode calibrated with 
Aldrich buffer solutions of pH 4, 7 and 10.  
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Determination of pKa Values. To generate the aqua complexes, chlorido 
complexes were dissolved in D2O and 0.98 mol equiv of AgNO3 were added. The 
solution was stirred for 24 h at 298 K, and AgCl was removed by filtration. For 
determinations of pKa* values (pKa values for solutions in D2O), the pH* values of 
solutions of the aqua complexes in this study were varied from ca. pH* 2 to 10 by the 
addition of dilute NaOD and DClO4, and 
1
H NMR spectra were recorded. The 
chemical shifts of the chelating ligand protons and/or of the methyl protons of Cp
x
 
were plotted against pH*. The pH* titration curves were fitted to the 
Henderson-Hasselbalch equation, with the assumption that the observed chemical 
shifts are weighted averages according to the populations of the protonated and 
deprotonated species. These pKa* values can be converted to pKa values by use of the 
equation pKa = 0.929pKa* + 0.42 as suggested by Krezel and Bal
10
 for comparison 
with related values in the literature. 
Interactions with Nucleobases. The reaction of complexes 1–5 (ca. 1 mM) with 
nucleobases typically involved addition of a solution containing 1 mol equiv of 
nucleobase in D2O to an equilibrium solution of complexes 1–5 in 20% MeOD-d4/80% 
D2O (v/v). 
1
H NMR spectra of these solutions were recorded at 310 K after various 
time intervals. 
Cytotoxicity. The A2780 human ovarian cancer cell line was obtained from the 
ECACC (European Collection of Animal Cell Cultures, Salisbury, UK). The cells 
were maintained in RPMI 1640 media (supplemented with 10% fetal calf serum, 1% 
L-glutamine, and 1% penicillin/streptomycin). All cells were grown at 310 K in an 
humidified atmosphere containing 5% CO2. Stock solutions of the Ir
III
 complexes 
were firstly prepared in DMSO to assist dissolution (maximum final DMSO 
concentration 2%), and then diluted into 0.9% saline and medium (1:1). After plating 
5000 A2780 cells per well on day 1, Ir
III
 complexes were added to the cancer cells on 
day 3 at concentrations ranging from 0.05 μM to 50 μM. Cells were exposed to the 
complexes for 24 h, washed with PBS, supplied with fresh medium, and allowed to 
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grow for three doubling times (72 h). Protein content (proportional to cell survival) 
was then measured using the sulforhodamine B (SRB) assay.
11
 The standard errors are 
based on two independent experiments carried out in triplicate. 
 
Results 
Five Ir
III
 half-sandwich complexes of the type [(η5-Cpx)Ir(C^N)Cl], where Cpx is 
pentamethylcyclopentadienyl Cp*, or its phenyl (Cp
xph
) or biphenyl (Cp
xbiph
)
 
derivatives, and the C,N-chelating ligands are 2-(p-tolyl)pyridine (tpy, 1), 
2-phenylquinoline (phq, 2), 2-(2,4-difluorophenyl)pyridine (dfphpy, 3), or 
2-phenylpyridine (phpy, 4 and 5), were synthesized in good yields by reaction of the 
chelating ligand with the appropriate dimer [(η5-Cpx)IrCl2]2 in CH2Cl2. All the 
synthesized complexes were fully characterized by 
1
H NMR and 
13
C NMR 
spectroscopy, ESI-MS and CHN elemental analysis. All the complexes in this study 
are chiral, but no attempt was made to resolve them and racemates are used in the 
following studies. 
X-ray Crystal Structures. The X-ray crystal structures of [(η5-C5Me5)Ir(phq)Cl] 
(2) and [(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (5) were determined. The structures and 
atom numbering schemes are shown in Figure 1. Crystallographic data are shown in 
Table 1, and selected bond lengths and angles are listed in Table 2. Complexes 2 and 
5 adopt the expected half-sandwich pseudo-octahedral “three-leg piano-stool” 
geometry with the iridium bound to a η5-cyclopentadienyl ligand (Ir to ring centroid 
distances of 1.829 and 1.825 Å, respectively). The Ir−Cl bond distances are 2.3989(16) 
and 2.3886(8) Å for 2 and 5, respectively. The Ir−C(chelating ligand) bond lengths in 
2 and 5 [2.045(6) and 2.057(3) Å, respectively] are significantly shorter than the Ir−N 
bond lengths [2.128(5) and 2.080(3) Å, respectively]. For complex 5, the twist angle 
between the bound cyclopentadienyl ring and the central phenyl ring is 48.93°, while 
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that between the bound ring and the terminal phenyl ring is 28.50°. The phenyl rings 
are twisted by 21.55°. No intermolecular π-ring stacking in the unit cell is observed in 
the two crystal structures. 
 
 
 
 
 
 
Figure 1. X-ray crystal structures and atom numbering schemes for complexes 
[(η5-C5Me5)Ir(phq)Cl] (2) and [(η
5
-C5Me4C6H4C6H5)Ir(2-phpy)Cl] (5). 
 
Table 1. Crystallographic Data for [(η5-C5Me5)Ir(phq)Cl] (2) and 
[(η5-C5Me4C6H4C6H5)Ir(2-phpy)Cl] (5) 
 2 5 
formula C25H25ClIrN C32H29ClIrN 
MW 567.11 655.21 
cryst color  orange block orange block 
cryst size (mm) 0.40 × 0.40 × 0.10 0.22 × 0.18 × 0.12 
λ (Å) 0.71073 0.71073 
temp (K) 100 100 
cryst syst orthorhombic monoclinic 
space group P2(1)2(1)2(1) P2(1)/n 
a (Å) 8.05090(13) 10.0094(4) 
b (Å) 15.9169(3) 22.9497(6) 
c (Å) 16.0586(3) 11.2128(4) 
α (°) 90 90 
β (°) 90 103.473(3) 
γ (°) 90 90 
vol(Å
3
) 2057.84(6) 2504.84(14) 
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Z 4 4 
density(calc) (Mg·m
−3
) 1.830 1.737 
abs coeff (mm
−1
) 6.628 5.459 
F(000) 1104 1288 
θ range (deg) 3.11 to 30.45 3.10 to 29.33 
index ranges −11 ≤ h ≤ 6, −20 ≤ k ≤ 22, 
−22 ≤ l ≤ 11 
 
−13 ≤ h ≤ 12, −31 ≤ k ≤ 31, 
−14 ≤ l ≤ 15 
 reflections collected 10123 23877 
independent reflections 5496 [R(int) = 0.0266] 6211 [R(int) = 0.0542] 
data/restraints/params 5496/0/253 6211/0/320 
final R indices [I > 2σ(I)] R1 = 0.0368, wR2 = 0.0856 R1 = 0.0293, wR2 = 0.0680 
R indices (all data) R1 = 0.0407, wR2 = 0.0886 R1 = 0.0377, wR2 = 0.0699 
GOF 1.053 0.999 
largest diff peak and hole  
(e Å
−3
) 
6.037 and −1.728 1.754 and −2.149 
Table 2. Selected Bond Lengths (Å) and Angles (deg) for [(η5-C5Me5)Ir(phq)Cl] (2) 
and [(η5-C5Me4C6H4C6H5)Ir(2-phpy)Cl] (5) 
Bond(s) 2 5 
Ir−C(Cpx)  2.139(6) 2.151(3) 
 2.157(6) 2.163(3) 
 2.167(5) 2.183(3) 
 2.243(6) 2.240(3) 
 2.304(6) 2.243(3) 
Ir−C(centroid) 1.829 1.825 
Ir−C 2.045(6) 2.057(3) 
Ir−N 2.128(5) 2.080(3) 
Ir−Cl 
Ir−Ir 
 
2.3989(16) 2.3886(8) 
C Ir−N 77.4(2) 78.27(13) 
C−Ir−Cl 89.66(17) 88.20(9) 
N−Ir−Cl 87.23(13) 86.34(8) 
 
Hydrolysis Studies. The hydrolysis of complexes 1–5 in 20% MeOD-d4/80% D2O 
(v/v) was monitored by 
1
H NMR spectroscopy at different temperatures. The presence 
of methanol ensured the solubility of the complexes. All these Ir
III
 complexes undergo 
rapid hydrolysis. Equilibrium was reached by the time the first 
1
H NMR spectrum was 
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acquired (~5 min) even at 278 K. At equilibrium 20%–50% of complex 1–5 was in 
the hydrolyzed form, based on 
1
H NMR peak integrals. 
To confirm the hydrolysis of the complexes, NaCl was added to equilibrium 
solutions containing the chlorido complexes and their aqua adducts to final 
concentrations of 4, 23 and 104 mM NaCl, mimicking the chloride concentrations in 
cell nucleus, cell cytoplasm and blood plasma, respectively.
12
 
1
H NMR spectra were 
then recorded within 10 min of the Cl
−
 additions at 298 K. Upon addition of NaCl, the 
1
H NMR peaks corresponding to the chlorido complexes increased in intensity whilst 
peaks for the aqua adducts decreased, Figures 2 and S1. These data confirm the 
formation of the aqua adducts and the reversibility of the process. On the basis of 
1
H 
NMR data, anation of aqua complexes 1A−5A was almost complete in 104 mM [Cl−] 
or in 23 mM [Cl
−
], and ca. 5% of aqua complex was observed at 4 mM [Cl
−
] after 10 
min with no further change after 24 h.  
 
 
 
 
 
 
 
 
 
Figure 2. Confirmation of hydrolysis of Ir
III
 complex [(η5-C5Me5)Ir(tpy)Cl] (1). (A) 
1
H NMR spectrum of an equilibrium solution of 1 (1 mM) in 20% MeOD-d4/80% 
D2O (v/v) at 298 K. (B) 
1
H NMR spectrum recorded 10 min after addition of NaCl 
(final concentration, 4 mM) to the equilibrium solution of 1. Complex 1A corresponds 
to the aqua complex [(η5-C5Me5)Ir(tpy)(D2O)]
 +
. The peaks for the chlorido complex 1 
increased in intensity while peaks for the aqua complex 1A decreased (ca. 5% 1A 
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remaining) upon addition of NaCl. 
 
pKa* Determination. Changes in the 
1
H NMR chemical shifts of the methyl 
protons of Cp* or protons of the coordinated chelating ligands in aqua complexes 
1A−5A and [(η5-C5Me5)Ir(phpy)(D2O)]
+
 (for comparison), were followed with 
change in pH* over a range of 2−10 (Figure S2). 1H NMR peaks assigned to aqua 
complexes gradually shifted to high field with increase in pH*. The resulting pH 
titration curves were fitted to the Henderson-Hasselbalch equation, from which the 
pKa* values of the coordinated water were determined. This gave pKa values between 
8.31 and 8.87 (Table 3), with the Cp
xbiph
 aqua complex 5A and fluoro-substituted 
phenylpyridine Cp* complex 3A having the lowest pKa values (8.31 and 8.32, 
respectively) and the methyl-substituted phenylpyridine complex 1A having the 
highest (8.87).  
Table 3. pKa* and pKa Values
a
 for the Deprotonation of the Coordinated D2O in 
Complexes 1A−5A and [(η5-C5Me5)Ir(phpy)(D2O)]
+
 
Aqua Complex pKa* pKa 
[(η5-C5Me5)Ir(tpy)(D2O)]
+
 (1A) 9.10 8.87 
[(η5-C5Me5)Ir(phq)(D2O)]
+
 (2A) 8.86 8.65 
[(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (3A) 8.51 8.32 
[(η5-C5Me4C6H5)Ir(phpy)(D2O)]
+
 (4A) 8.64 8.45 
[(η5-C5Me4C6H4C6H5)Ir(phpy)(D2O)]
+
 (5A) 8.50 8.31 
[(η5-C5Me5)Ir(phpy)(D2O)]
+
  8.97 8.75 
a
 pKa values calculated from pKa* according to Krezel and Bal.
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During the pH titrations for aqua complexes 1A−5A, the appearance of a new set of 
peaks was detected with increasing pH* (>8.7). The new peaks are attributable to the 
free C,N-chelating ligands and to the hydroxo-bridged dimers {[(η5-Cpx)Ir]2(μ-OD)3}
+
 
(Cp
x
 = Cp*, 6; Cp
xph
, 7; Cp
xbiph
, 8, see Chart 1). The 
1
H NMR peaks for 
hydroxo-bridged dimers 6−8 increased in intensity with increase in pH*. For complex 
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[(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (3A), the amount of dimer 6 increased from 23% at 
pH* 9.0 to 50% at pH* 9.6, Figure 3. ESI-MS studies on the diluted sample (0.2 mM) 
gave a major peak at m/z 709.2, consistent with the presence of 
{[(η5-C5Me5)Ir]2(μ-OD)3}
+
 (calcd m/z 710.2).  
 
 
 
 
 
 
 
 
 
 
Figure 3. Methyl region of 
1
H NMR spectra from the pH titration of the aqua 
complex [(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (3A), showing an increase in intensity of the 
peak for the hydroxo-bridged dimer {[(η5-C5Me5)Ir]2(μ-OD)3}
+
 (6) with increase in 
pH*. 
 
Interactions with Nucleobases. Since DNA is a potential target for transition 
metal anticancer drugs,
13
 nucleobase binding reactions of complexes 
[(η5-C5Me5)Ir(tpy)Cl] (1), [(η
5
-C5Me5)Ir(phq)Cl] (2), [(η
5
-C5Me5)Ir(dfphpy)Cl] (3), 
[(η5-C5Me4C6H5)Ir(phpy)Cl] (4) and [(η
5
-C5Me4C6H4C6H5)Ir(phpy)Cl] (5), with 
9-ethylguanine (9-EtG) and 9-methyladenine (9-MeA) were investigated. Solutions of 
1−5 (ca. 1 mM, containing an equilibrium mixture of 1−5 and their respective aqua 
adducts 1A−5A) and 1 mol equivalent of 9-EtG or 9-MeA in 20% MeOD-d4/80% 
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D2O (v/v) were prepared, and 
1
H NMR spectra were recorded at different time 
intervals at 310 K. The percentages of nucleobase adducts formed by the complexes 
after 24 h reaction, based on 
1
H NMR peak integrals, are shown in Table S1 and 
Figure 4.  
 
 
 
 
 
 
 
Figure 4. Bar chart showing the extent of binding of complexes 1−5 (ca. 1 mM in 20% 
MeOD-d4/80% D2O) to the nucleobases 9-EtG and 9-MeA at equilibrium (24 h), 
based on 
1
H NMR peak integrals. 
 
In the 
1
H NMR spectrum of a solution containing 4 (0.8 mM) and 1 mol equiv 
9-ethylguanine (20% MeOD-d4/80% D2O, pH* 7.4, 310 K), one set of new peaks 
assignable to the 9-EtG adduct 4G appeared, showing that 100% of 4 had reacted 
after 10 min (Figure S3). A significant change in chemical shift from 8.62 ppm for the 
chlorido complex 4 to 9.28 ppm for 9-EtG adduct 4G for the CH=N (phpy ligand) 
proton was observed. A new 9-EtG H8 peak appeared at 7.44 ppm (singlet), shifted 
by 0.34 ppm to high field relative to that of free 9-EtG. After 24 h, no further change 
was observed. The ESI-MS of an equilibrium solution contained a major peak at m/z 
723.2, confirming the formation of the 9-EtG adduct 4G, 
[(η5-C5Me4C6H5)Ir(phpy)(9-EtG)]
+
 (calcd m/z 722.9). Similarly, complexes 1, 3 and 5 
also formed 9-EtG adducts to the extent of 100% after 24 h. Only complex 2 
containing 2-phenylquinoline showed less strong binding to 9-EtG (45%, Figure 4 and 
Table S1). 
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Complexes 3−5 formed moderately strong 9-MeA adducts (35−63% at equilibrium 
after 24 h, Table S1). Only complex 1 [(η5-C5Me5)Ir(tpy)Cl] showed an exceptionally 
high affinity for 9-MeA, with 90% adduct formation after 24 h. Complex 2 containing 
2-phenylquinoline formed almost no 9-MeA adduct (<5%). Except for 2, two adenine 
nucleobase adducts were formed in the reactions between complexes 1, 3−5 with 
9-MeA, most likely through iridium binding to N1 or N7 of adenine in a ratio 
typically of 1:5. 
Competition reactions between equi-molar amounts of 9-EtG and 9-MeA and 
complexes 1, and 3−5 (ca. 1 mM) in 20% MeOD-d4/80% D2O (v/v, pH* ca. 7.4) at 
310 K were investigated. In the competitive experiment, 9-EtG adducts 3G, 4G or 5G 
were observed as the only product for complexes 3−5, and as 80% 9-EtG adduct for 
complex 1 (20% 9-MeA adduct), Table S1. The 
1
H NMR spectra for the competition 
reaction for 3 are shown in Figure 5. 
 
 
 
 
 
 
Figure 5. Low field region of the 
1
H NMR spectra for the competitive reaction 
between 9-EtG and 9-MeA and complex 3 [(η5-C5Me5)Ir(dfphpy)Cl].
 
(A) Equilibrium 
solution of 3 (1.0 mM) in 20% MeOD-d4/80% D2O (v/v, pH* 7.4) at 310 K, 
containing both the chlorido complex 3 and its aqua adduct 3A. (B) 10 min after 
addition of equimolar amounts of 9-EtG and 9-MeA, showing the complete formation 
of 9-EtG adduct 3G.  
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Figure 6. Low field region of the 
1
H NMR spectra for the reaction between 9-EtG and 
complex 4 [(η5-C5Me4C6H5)Ir(phpy)Cl] at 310 K.
 
(A) Equilibrium solution of 4 (0.8 
mM) in 20% MeOD-d4/80% D2O (v/v, pH* 7.4), containing both the chlorido 
complex 4 and its aqua adduct 4A. (B) 10 min after addition of NaCl (final 
concentration, 4 mM) to the equilibrium solution. (C) The complete formation of 
9-EtG adduct 4G after addition of 1 mol equiv 9-EtG.  
 
Reactions of complexes [(η5-C5Me4C6H5)Ir(phpy)Cl] (4) and 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (5) with 9-EtG were also investigated in the 
presence of 4 mM NaCl, Figure 6. A solution of 4 (ca. 0.8 mM) in 20% MeOD-d4/80% 
D2O (v/v) containing an equilibrium mixture of 4 and aqua adduct 4A was prepared, 
and its 
1
H NMR spectrum was recorded, Figure 6A. Then NaCl was added to give a 4 
mM [Cl
−
] solution. The aqua adduct 4A was suppressed to ca. 5%, Figure 6B. 
Addition of ca. 1 mol equivalent of 9-EtG resulted in complete formation of 9-EtG 
adduct after 24 h at 310 K. Complex 5 also formed a guanine adduct quantitatively in 
the presence of 4 mM [Cl
−
]. 
Cytotoxicity. The cytotoxicity of complexes 1−5 towards A2780 human ovarian 
cancer cells was investigated, Table 4. The IC50 value (concentration at which 50% of 
the cell growth is inhibited) for Cp* Ir
III
 complexes 1−3 is comparable with that of 
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cisplatin. Complexes 4 and 5 containing Cp
xph 
or Cp
xbiph
 were even more potent, 
especially complex 5 with an IC50 value of 0.7 μM (ca. twice as active as cisplatin). 
Overall, the cytotoxic potency increases with phenyl substitution on Cp*: Cp
xbiph
 > 
Cp
xph
 > Cp*, Table 4 and Figure S4. 
 
Table 4. Inhibition of Growth of A2780 Human Ovarian Cancer Cells by Complexes 
1−5 and Comparison with Cisplatin 
Complex IC50
 a
 (μM) 
[(η5-C5Me5)Ir(tpy)Cl] (1) 3.28±0.14 
[(η5-C5Me5)Ir(phq)Cl] (2) 2.55±0.03  
[(η5-C5Me5)Ir(dfphpy)Cl] (3) 6.53±0.50 
[(η5-C5Me4C6H5)Ir(phpy)Cl] (4) 2.14±0.50 
[(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (5) 0.70 ±0.04  
[(η5-C5Me5)Ir(phpy)Cl]
 b
 10.78 ±1.72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cisplatin 1.19±0.12 
a
 Drug-treatment period was 24 h. 
b 
Ref 3b. 
 
Discussion 
X-ray Crystal Structures. A search of the Cambridge Crystallographic Database 
showed that the crystal structure of complex 5 is only the second example to be 
reported of a metal complex containing the Cp
xbiph
 ligand. The only other example is 
the bipyridine complex [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6 (where bpy = 
bipyridine).
3a
 The two complexes are structurally very similar. In complex 5, the 
chelating ligand is closer to the Ir
III
 center than in [(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6 
since the Ir−C bond length [2.057(3) Å] in complex 5 is significantly shorter than the 
Ir−N bond length [2.091(5) Å]3a in the latter complex. The short Ir–C(phenylpyridine) 
distance causes a slight elongation of the Ir–cyclopentadienyl (centroid) bond with 
distance of 1.825 Å in complex 5 (Table 2), compared to 1.787 Å in complex 
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[(η5-C5Me4C6H4C6H5)Ir(bpy)Cl]PF6. The Ir–Cl bond lengths are similar in the two 
complexes, with distances of 2.3886(8) Å (Table 2) and 2.3840(14) Å,
3a
 respectively. 
This behavior is similar to that observed for the C,N-chelated complex 
[(η5-C5Me5)Ir(phpy)Cl]
14
 when compared to the N,N-chelated complex 
[(η5-C5Me5)Ir(bpy)Cl]Cl.
3b
 
The bond lengths and bond angles in complexes [(η5-C5Me5)Ir(phq)Cl] (2) and 
[(η5-C5Me5)Ir(phpy)Cl]
14
 are similar, except that the Ir−N bond for 2 [2.128(5) Å] is 
longer than that of [(η5-C5Me5)Ir(phpy)Cl] [2.080(2) Å], implying weaker σ donation 
from N to the iridium center due to the electron-withdrawing phenyl ring in the 
quinoline moiety.  
Hydrolysis and pKa of Aqua Adducts. Since M–OH2 (M = metal) aqua 
complexes are often more reactive than the equivalent chlorido complexes,
3a,12,15
 
hydrolysis of the M–Cl bonds can represent an activation step for transition metal 
anticancer complexes.
16
 There are only a few previous studies of the aquation 
(substitution of Cl by H2O) of organometallic Ir
III
 complexes.
3a,4a,17
 In the work 
reported here all the [(η5-Cpx)Ir(C^N)Cl] complexes 1−5 hydrolyzed too rapidly for 
determination of their hydrolysis rates by NMR, even for the biphenyl substituted 
Cp
xbiph
 complex 5 [(η5-C5Me4C6H4C6H5)Ir(2-phpy)Cl]. We have previously reported 
half-lives for the hydrolysis of some Cp
xph
 or Cp
xbiph
 Ir
III
 complexes containing 
N,N-bound 2,2′-bipyridine (bpy) or 1,10-phenanthroline (phen) chelating ligands of 
ca. 4 min at 310 K.
3a
 The electron-donor methyl groups on the Cp ring and the 
negatively-charged C,N-chelating ligands may together contribute to the fast 
hydrolysis observed for the complexes reported here since the increased effective 
charge on the Ir center may facilitate chloride loss. Fast hydrolysis rates also have 
been reported for some hexamethylbenzene Ru
II
 complexes,
18
 acetylacetonate Ru
II
 
and Os
II
 complexes,
19
 and picolinate Ir
III
 complexes.
3a
 These results illustrate that Ir
III
 
complexes are not always inert and that Ir−Cl bonds can be labile. 
At chloride concentrations typical of blood plasma (104 mM) and cell cytoplasm 
 20 
 
(23 mM), complexes 1−5 were found to be almost all present in solution as the 
relatively unreactive chlorido species, and only about 5% of complexes 1−5 was 
present as the reactive aqua species at a chloride concentration of 4 mM close to that 
of the cell nucleus. These data suggest that aquation is suppressed almost totally at the 
saline concentration in blood. However, complexes 1−5 might be activated by 
aquation in the cell nucleus. Another possibility is that the complexes might react by 
direct substitution of chloride by nucleobases (DNA).  
The aqua complexes [(η5-C5Me5)Ir(tpy)(D2O)]
+
 (1A), [(η5-C5Me5)Ir(phq)(D2O)]
+
 
(2A), [(η5-C5Me5)Ir(dfphpy)(D2O)]
+
 (3A), [(η5-C5Me4C6H5)Ir(phpy)(D2O)]
+
 (4A), 
[(η5-C5Me4C6H4C6H5)Ir(phpy)(D2O)]
+
 (5A), and [(η5-C5Me5)Ir(phpy)(D2O)]
+
, have 
similar pKa values, ranging from 8.31 to 8.87 (Table 3). Although the substituents on 
the Cp* ring and the 2-phenylpyridine chelating ligand do not significantly affect the 
acidity of the bound water, the observed trend caused by these substituents is clear, 
following the order 1A > 2A > 4A > 5A ≈ 3A. The presence of phenyl and biphenyl 
substituents on the Cp* ring lower the pKa value by ca. 0.3 to 0.4 units, consistent 
with the electron-withdrawing properties of these groups. Substitution of 
cyclometalated 2-phenylpyridine by the fluorinated chelating ligand 
2-(2,4-difluorophenyl)pyridine leads to a decrease in pKa by 0.4 units. However, 
replacing cyclometalated 2-phenylpyridine by 2-(p-tolyl)pyridine or by the more 
π-delocalized 2-phenylquinoline, has little effect on the pKa value (ca. 0.1 unit)  
However, the aqua complexes [(η5-C5Me5)Ir(phpy)(D2O)]
+
, 
[(η5-C5Me4C6H5)Ir(phpy)(D2O)]
+ 
(4A) and [(η5-C5Me4C6H4C6H5)Ir(phpy)(D2O)]
+
 (5A) 
containing the C,N-chelated 2-phenylpyridine ligand, have significantly higher pKa 
values (average 1.9 units higher) than those for the structurally similar Ir
III
 Cp
x
 
analogues bearing the N,N-bound 2,2'-bipyridine (bpy) ligand.
3a
 Therefore, the 
replacement of the neutral bpy ligand by the anionic phpy ligand plays a significant 
role in decreasing the acidity of the aqua complexes, consistent with previous 
reports.
3a,19a
 The high pKa values of 1A−5A thus ensure that most of the hydrolyzed 
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complexes would be present in the active aqua form at physiological pH. 
The pH titration also showed that additional species were formed for all complexes 
studied here above pH 8.7 (Figure 3), indicating the formation of the hydroxo-bridged 
dimers {[(η5-Cpx)Ir]2(μ-OD)3}
+
 (6−8, Chart 1). However, this does not occur when the 
chelating ligand is N,N-chelated bipyridine ligand.
3a
 Clearly the Ir−C bond shows less 
stability with respect to the formation of dimers 6−8 than the Ir−N bond. It seems 
likely that the mechanism of formation of 6−8 involves initial cleavage of the Ir−C 
bond, followed by Ir−N bond breakage. Some OsII and RuII complexes containing 
N,O-bound or O,O-bound ligands have been reported to form hydroxo-bridged dimers 
readily during their hydrolysis, resulting in their inactivity toward cancer cell lines.
20
 
In this work, no hydroxo-bridged dimers of 6−8 were observed during hydrolysis, and 
all the complexes are active toward A2780 human ovarian cancer cells. This indicates 
that the C,N-chelated Ir
III
 complexes are stable in aqueous solution and the dimers 
6−8 formed only appear at high pH and have no negative effect on their cytotoxicity 
at physiological pH. 
Interactions with Nucleobases. Interaction with DNA is often associated with the 
cytotoxicity of metal anticancer drugs.
13
 In this study, the interactions with model 
nucloebases, 9-EtG and 9-MeA, and with complexes 1−5 were investigated (Figure 4 
and Table S1). All the C,N-chelated Ir
III
 complexes, except 2, showed an 
exceptionally high nucleobase affinity with 100% guanine adduct formation for 9-EtG, 
which may contribute to their high cytotoxicity. Complexes 
[(η5-C5Me4C6H5)Ir(phpy)Cl] (4) and [(η
5
-C5Me4C6H4C6H5)Ir(phpy)Cl] (5) still bind 
strongly to guanine in the presence of 4 mM [Cl
−
] (typically the chloride 
concentration in cell nucleus) (Figure 6), which suggests that this class of iridium 
complexes might interact with DNA in the cell nucleus. Compared with N,N-chelated 
Ir
III
 complexes,
3a
 complexes containing a C,N-bound chelating ligand bind more 
significantly to 9-EtG, which may be due to their inherent advantage of having higher 
pKa values. Under similar pH conditions, hydrolyzed C,N- complexes are more likely 
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to be present as the reactive aqua form compared to the N,N-chelated complexes. 
Complexes 1−5 bind more weakly to adenine compared to guanine. The 
competition between 9-EtG and 9-MeA for the C,N-bound Ir
III
 complexes give rise to 
9-EtG adducts as the only product for 3−5 and as major product for 1 (Figure 4 and 
Table S1), confirming that binding to guanine is stronger than to adenine. This may 
due to the steric hindrance caused by the NH2 group at the 6-position of the adenine 
ring. In addition, guanine is usually considered to be a stronger electron donor than 
adenine.
21
 The widely used anticancer drug in clinical, cisplatin, also prefers guanine 
over adenine.
22
 Organometallic Ru
II
, Os
II
 and Ir
III
 complexes containing 
N,O-chelating ligands or O,O-chelating ligands such as picolinate and acetylacetonate, 
which possess oxygen as an H-bond acceptor for adenine C6NH2, also bind to both 
guanine and adenine residues.
3a,19a,20b,23
 
Ir
III
 cyclopentadienyl complexes containing a neutral N,N-chelating ligand (phen, 
bpy, or ethylenediamine) bind selectively to 9-EtG, but not to adenine.
3a
 The 
formation of adenine adducts in this work may be due to the interaction between NH2 
of 9-MeA and negatively-charged carbons on the C,N-chelating ligand.
3b
 Thus 
complexes 1−3 containing different substituents on the phenylpyridine bind to 9-MeA 
differently. The electron donating methyl group on the phenyl ring in complex 
[(η5-C5Me5)Ir(tpy)Cl] (1) increases electron density and may facilitate the interaction 
with 9-MeA (>90%). In contrast, only 35% of complex [(η5-C5Me5)Ir(dfphpy)Cl] (3) 
formed 9-MeA adducts which may be due to the presence of the electron-withdrawing 
fluoro group. Complex 2 [(η5-C5Me5)Ir(phq)Cl] has the lowest affinity for both model 
nucleobases among the five complexes, with 45% and <5% binding to 9-EtG and 
9-MeA, respectively. The weaker binding is most likely due to the steric hindrance 
caused by the quinoline ligand.  
Cytotoxicity. We have reported that some Cp* Ir
III
 complexes containing N,N-, or 
N,O-chelating ligands are inactive toward A2780 human ovarian cancer cells.
3a
 
However, all Cp* complexes [(η5-C5Me5)Ir(tpy)Cl] (1), [(η
5
-C5Me5)Ir(phq)Cl] (2), 
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and [(η5-C5Me5)Ir(dfphpy)Cl] (3) studied here showed promising activity toward the 
human ovarian A2780 cancer cell line with IC50 values ranging from 2.5−6.5 μM 
(Table 4), close to the value we reported recently for [(η5-C5Me5)Ir(phpy)Cl].
3b
 Thus 
the introduction of C,N-chelating ligands is an effective method for switching on the 
cancer cell cytotoxicity of Cp* Ir
III
 complexes. The strong binding of Ir to 
nucleobases, especially to guanine bases, may provide an important contribution 
towards the cytotoxicity. Also the neutral C,N- complexes display a more 
hydrophobic character than the positively-charged N,N- complexes
3b
 and therefore 
possess enhanced cellular uptake which may also contribute to the cytotoxicity. The 
introduction of substituents on the phenylpyridine ring enhanced the cytotoxicity of 
[(η5-C5Me5)Ir(phpy)Cl], Table 4. Particularly active is the complex 
[(η5-C5Me5)Ir(phq)Cl] (2), which is 4 times as potent as [(η
5
-C5Me5)Ir(phpy)Cl]. The 
ability of the phq ligand to intercalate into DNA
24
 may contribute to this enhanced 
potency. 
The introduction of phenyl or biphenyl substituents onto the 
tetramethylcyclopentadienyl ring to give complexes [(η5-C5Me4C6H5)Ir(phpy)Cl] (4) 
and [(η5-C5Me4C6H4C6H5)Ir(phpy)Cl] (5), results in a dramatic increase in 
cytotoxicity compared to the parent Cp* complex [(η5-C5Me5)Ir(phpy)Cl], Table 4 
and Figure S4. The activity of Ru
II
 arene complexes also increases with the size of the 
coordinated arene.
25
 This suggests that these phenyl groups may play a crucial role in 
the mechanism of action of these phenylpyridine complexes. First, the phenyl or 
biphenyl ring increases the hydrophobicity of the molecule, which may assist with 
passage across cell membranes. In addition, the extended phenyl rings can intercalate 
into DNA, thus causing distortion of DNA structure. We have reported that the 
intercalative ability of 1,10-phenanthroline Ir
III
 chlorido complexes increases in the 
order of Cp
xbiph
 > Cp
xph
 > Cp*.
3a
 Complexes 4 and 5 containing phenyl or biphenyl 
substitutions may interact with DNA by a dual mode: nucleobase binding to iridium 
accompanied by intercalation of the phenyl groups, which is a different mechanism of 
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action from that of cisplatin.  
 
Conclusions 
Iridium-based anticancer agents, including organometallic iridium complexes, are 
currently attracting attention as potential anticancer agents with novel mechanisms of 
action. We have studied here the effects of changing the Cp
x
 ligand and 
negatively-charged C,N-chelating ligand of Ir
III
 cyclopentadienyl complexes of the 
type [(η5-Cpx)Ir(C^N)Cl] on the hydrolysis of the chlorido complex, acidity of the 
aqua adduct, nucleobase binding, and cancer cell cytotoxicity. 
All the complexes undergo rapid hydrolysis (<5 min at 278 K) due to the strongly 
electron-donating methyl group and negatively-charged C,N-chelating ligand. 
However the complexes are likely to be present in their unhydrolyzed forms in the 
extracellular fluid and cell cytoplasm (typically 104 and 23 mM [Cl
−
]), whereas they 
are likely to be activated by hydrolysis in the cell nucleus ([Cl
−
] ca. 4 mM). Generally, 
the aqua adducts of the C,N- complexes studied here possess low acidity, with pKa 
values 1.9 units higher than N,N- analogues, which ensures that the active aqua 
adduct is the major form after hydrolysis at physiological pH, and may contribute to 
the strong binding to guanine. The substituents on both the Cp* ring and on 
2-phenylpyridine can fine-tune the acidity of aqua adduts according to their electronic 
effects. Hydroxo-bridged dimers {[(η5-Cpx)Ir]2(μ-OD)3}
+
 (6–8) are observed at high 
pH (>8.7), which suggests the stability of C,N- complexes is not as high as N,N- 
analogues under strongly basic conditions.  
Complexes 1 and 3–5 show strong binding to the nucleobase guanine, even in the 
presence of 4 mM [Cl
−
]. Unlike the Ir
III
 complexes containing N,N-chelating 
ligands,
3a
 the C,N- complexes can also bind to adenine. However, they show a strong 
preference for binding to guanine over adenine. Complex 2 displayed the lowest 
extent of nucleobase binding among the complexes studied due to steric hindrance 
from the chelating ligand 2-phenylquinoline.  
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All the C,N- complexes showed very promising anticancer activity toward A2780 
human ovarian cancer cells. The Cp* complexes possess activity comparable to 
cisplatin. The introduction of phenyl or biphenyl substituent significantly improved 
their cytotoxicity, especially for the Cp
xbiph
 complex 5 which has submicromolar 
activity against A2780 cancer cells. The strong binding to guanine bases and 
hydrophobicity may contribute to their high activity. This study shows that desirable 
features can be introduced into this class of complexes to optimize their design as 
anticancer agents. 
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